Startup profile · funding coverage
ROME Therapeutics
Biotech targeting the genomic 'repeatome' for cancer and autoimmune disease.
Stage
series b
Status
private
Coverage
full
Why ROME Therapeutics is interesting
ROME maps repetitive DNA once dismissed as junk to find innate-immune drug targets — ARCH and GV incubated the company before a16z joined later rounds.
Key facts
- Series A (Apr 2020): $50M co-led by GV and ARCH Venture Partners (ROME press)
- Series B extension (Sep 2023): $72M with a16z, ARCH, GV participation (ROME press)
- Source: https://rometx.com/press-releases/rome-therapeutics-launches-to-develop-novel-therapies-for-cancer-and-autoimmune-diseases-by-harnessing-the-power-of-the-repeatome/
Investors in our directory
Funds linked from ROME Therapeutics's profile — open a fund page for stage focus and related deal articles.
Industries
Biotech & Life Sciences
Industry hub pages are rolling out from our fund-derived baseline taxonomy.
Related funding articles
Venture Capital Tracker pieces that cover ROME Therapeutics's financing or category context.
Last updated: 2026-07-24